INSOMNIA is the #6 most commonly reported adverse reaction for VARENICLINE TARTRATE, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 5,566 FDA adverse event reports linking VARENICLINE TARTRATE to INSOMNIA. This represents approximately 3.3% of all 167,559 adverse event reports for this drug.
VARENICLINE TARTRATE has an overall safety score of 85 out of 100. Patients taking VARENICLINE TARTRATE who experience insomnia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
Reporting Frequency
INSOMNIA5,566 of 167,559 reports
INSOMNIA is moderately reported among VARENICLINE TARTRATE users, representing a notable but not dominant share of adverse events.
Other Side Effects of VARENICLINE TARTRATE
In addition to insomnia, the following adverse reactions have been reported for VARENICLINE TARTRATE:
INSOMNIA has been reported as an adverse event in 5,566 FDA reports for VARENICLINE TARTRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
How common is INSOMNIA with VARENICLINE TARTRATE?
INSOMNIA accounts for approximately 3.3% of all adverse event reports for VARENICLINE TARTRATE, making it a notable side effect.
What should I do if I experience INSOMNIA while taking VARENICLINE TARTRATE?
If you experience insomnia while taking VARENICLINE TARTRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.
Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.